- Question from WallyC: Has there been a determination for the intermediate OncotypeDX score and chemo cut-off for node-negative?
Kathy D. Miller, M.D.
No. We still struggle with the potential benefits of chemotherapy for women with ER-positive tumors that have intermediate Oncotype DX scores. In this group, there may be no benefits from chemotherapy or the benefit may be as high as 4-5%. That leaves women and their oncologists with very difficult decisions. This is essentially the difficult decision that all women faced before the Oncotype test was able to identify the low and high risk groups. This is why the current TAILORx trial, which randomizes patients with intermediate scores to hormone therapy alone or hormone therapy plus chemotherapy is so important. We suspect that many women in the intermediate group don't need chemotherapy, but the current test simply can't clearly identify them.
Editor’s note: Since this research was published, new genomic tests have come to market. For the most up-to-date information, visit the Breastcancer.org Breast Cancer Tests page.
The Ask-the-Expert Online Conference called Updates From the 2009 San Antonio Breast Cancer Symposium featured Kathy Miller, M.D. and Kristin Brill, M.D., F.A.C.S. answering your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.
Editor's Note: This conference took place in December 2009.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.